In human melanoma cells, EGF treatment can promote STAT5 activation via tyrosine-protein kinase Src (Src) and Janus kinase 1 (JAK1) signaling leading to STAT5 nuclear translocation along with upregulation of the STAT5 target, Bcl-2, an antiapoptosis protein [60]. The gene discussed is EGF; the disease is melanoma.